No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Neupath Health Appoints Stephen Lemieux as President
NEUPATH HEALTH THE FIRST NORTH AMERICAN PROVIDER OF ARTHROSAMID, A REVOLUTIONARY INJECTION FOR KNEE OSTEOARTHRITIS
NEUPATH HEALTH ANNOUNCES ISSUANCE OF STOCK OPTIONS AND RESTRICTED SHARE UNITS
NEUPATH HEALTH ANNOUNCES APPROVAL OF NORMAL COURSE ISSUER BID
NEUPATH HEALTH TO BE FEATURED ON RADIUS RESEARCH'S PITCH, DEEP DIVE AND Q&A WEBINAR
Earnings Flash: Neupath Health Q2 Revenue $18.9 Million, Up 11% From 2023